Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the nam